Coronavirus Disease (COVID-19)ExploreNCT04346056
Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19
An observational study of Coronavirus Disease (COVID-19) and COVID-19, run by Ain Shams University at 2 sites in Egypt.
Trial summary
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR Read more about this study
- Who is it for?
- Ages 1 year to 80 years
- Conditions the study is for
- Coronavirus Disease (COVID-19), COVID-19
- How many people
- 500 participants
- Where
- 2 sitesEgypt
- Study dates
- 14 Apr 2020to 1 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: hospitalized patients who meet the WHO standard SARI case definition
Who may be able to join
- 500 case presented from November 2019-February 2020 will be included in explore study from Ain shams university Hospitals
Who cannot join
- Inadequate samples
Trial locations and contacts
2 sites in 1 country.
Egypt2 sites, 2 recruiting
- Recruiting
Faculty of Medicine Ain Shams University
Cairo, Non-US, 11556
Fatma Soliman E Ebeid, 01095569596, dr.fatma_ebeid@yahoo.com
- Recruiting
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
Cairo, Non-US, 11566
Fatma Soliman E Ebeid, 01095569596, dr.fatma_ebeid@yahoo.com
About this study
Official title: Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR
Read the detailed description
A- Methodology adopted in the retrospective study:
Sample Size Determination:
500 case presented from November 2019- February 2020 will be included in explore study from Ain shams university Hospitals
Collection of Samples:
Oropharyngeal and nasopharyngeal swabs (NP) for hospitalized SARI patients:
Clinicians in the internal medicine, chest, and pediatric hospitals will be responsible for obtaining oropharyngeal and nasopharyngeal swabs for laboratory testing from all hospitalized patients who meet the WHO standard SARI case definition.
Oropharyngeal swabbing:
A dry sterile tip flocked with nylon fiber swab applicator should be used to swab the posterior pharynx. The swab should be placed in a 15 ML centrifuge tube labeled with the patient unique ID and containing 2mL viral transport media (VTM). The applicator stick is then cut off.
Nasopharyngeal swabbing:
A flexible, sterile tip flocked with nylon fiber swab applicator is inserted into the nostril and back to the nasopharynx and left in place for a few seconds. It is then slowly withdrawn with a rotating motion. For SARI patients, the swab is put into the same centrifuge tube as the oropharyngeal swab labeled with the patient's unique ID and the shaft is cut. The 15 ml tube containing the swab/s should be carefully transported to the hospital laboratory as soon as possible in cold chain.
Sample processing:
The received swabs inside the 15 ml tube should be agitated vigorously for 10 seconds using a vortex mixer to free cells from the swab tip, and then both swabs should be removed from the tube and discarded using a forceps. The VTM should be split into 2 pre-labeled, sterile cryovials with the correct patient ID. One cryovial should be immediately placed in a freezer (-70°C), while the other cryovial will be used the molecular testing by real time PCR at MASRI-molecular laboratory.
Samples will be tested by real time multiplex PCR using FTD- respiratory 33 kit for the presence of a wide panel of respiratory pathogens that include: influenza A and subtypes influenza A Pdm(H1N1) and seasonal H3, influenza B, influenza C, parainfluenza viruses 1, 2, 3 and 4; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A and B; rhinovirus; respiratory syncytial viruses A and B ; adenovirus; enterovirus; parechovirus; Boca virus; Pneumocystis jirovecii; Mycoplasma pneumoniae; Chlamydia pneumoniae; Streptococcus pneumoniae; Haemophilus influenza type B (HIB assay also detects Haemophilus parahaemolyticus which is associated with pharyngitis); Staphylococcus aureus; Moraxella catarrhalis; Bordetella spp. (except Bordetella parapertussis), Klebsiella pneumoniae; Legionella species and Salmonella species. Cases suspected with MERS-CoV or HPAI H5N1 according to their history of contact with birds or camels or with reference to the WHO suspected cases of MERS-CoV or avian influenza will be tested using the CDC protocol.
Sample storage:
The second aliquot of the samples will be stored in freezers (-70°C) at MASRI MOLECULAR laboratory for External Quality Assurance (EQA) by on site testing through random selection of samples with different results and retest them by other NAMRU-3 laboratory expertise in MASRI molecular labs; the samples can also be used for further testing by NGS or virus isolation in MASRI molecular laboratories.
Sample Transfer:
All samples will be kept in Faculty of Medicine Ain Shams Research Institute- Molecular Unit laboratories and will not be transferred to other laboratories.
B- Explore study testing for COVID-19 using ready to use RT-real time test assays - VIRAL RNA ISOLATION: Using commercially available kits supplied by thermofisher or other recommended companies. Work will be done in Biosafety level 2 cabinets under complete sterile conditions. -
COVID-19 DETECTION:
Using real-time reverse transcription polymerase chain reaction RT-PCR the test can be done on respiratory samples obtained by various methods, including nasopharyngeal swab or sputum sample. Results are generally available within a few hours. Molecular methods leverage polymerase chain reaction (PCR) along with nucleic acid tests, and other advanced analytical techniques, to detect the genetic material of the virus using real-time reverse transcription polymerase chain reaction for diagnostic purposes. Commercially available kits supplied by hvd, thermofisher and others.
C- Genome sequencing (NGS) for possible positive covid-19 samples Ion Torrent targeted next-generation sequencing (NGS) enables a streamlined research workflow for complete genome sequencing and epidemiological studies of SARS-CoV-2 (the coronavirus responsible for COVID-19). Through the use of a set of highly specific, universal coronavirus primers in combination with a high-fidelity master mix, all genomic segments are amplified and the DNA amplicons are sequenced on any Ion Torrent system to deliver highly accurate coronavirus typing in under a day. The Ion ArnpliSeq SARS-CoV-2 Research Panel consists of 2 pools with arnplicons ranging from 125275 bp iri length for complete viral genome sequencing
- Conditions
- Coronavirus Disease (COVID-19), COVID-19
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Exploring the presence of COVID-19
Exploring the presence of COVID-19 in very well preserved oropharyngeal samples since November 2019
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2020
- Study start14 Apr 2020
- Primary completion1 Oct 2020 (estimated)
- Study completion1 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronavirus Disease (COVID-19)Studies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Hassan Agwa, Ain Shams University
- Investigators
- Sara Hassan, Principal investigator, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04346056
- Sponsor's protocol ID
- FMASU P17a/ 2020
- Acronym
- Explore
- Status last verified
- Apr 2020
- First submitted
- 13 Apr 2020
- Last updated
- 20 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR
- ClinicalTrials.gov ID
- NCT04346056
- Acronym / sponsor ID
- Explore / FMASU P17a/ 2020
- Conditions
- Coronavirus Disease (COVID-19), COVID-19
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 14 Apr 2020 (actual)
- Primary completion
- 1 Oct 2020 (estimated)
- Study completion
- 1 Dec 2020 (estimated)
- First posted
- 15 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR
Detailed description
A- Methodology adopted in the retrospective study:
Sample Size Determination:
500 case presented from November 2019- February 2020 will be included in explore study from Ain shams university Hospitals
Collection of Samples:
Oropharyngeal and nasopharyngeal swabs (NP) for hospitalized SARI patients:
Clinicians in the internal medicine, chest, and pediatric hospitals will be responsible for obtaining oropharyngeal and nasopharyngeal swabs for laboratory testing from all hospitalized patients who meet the WHO standard SARI case definition.
Oropharyngeal swabbing:
A dry sterile tip flocked with nylon fiber swab applicator should be used to swab the posterior pharynx. The swab should be placed in a 15 ML centrifuge tube labeled with the patient unique ID and containing 2mL viral transport media (VTM). The applicator stick is then cut off.
Nasopharyngeal swabbing:
A flexible, sterile tip flocked with nylon fiber swab applicator is inserted into the nostril and back to the nasopharynx and left in place for a few seconds. It is then slowly withdrawn with a rotating motion. For SARI patients, the swab is put into the same centrifuge tube as the oropharyngeal swab labeled with the patient's unique ID and the shaft is cut. The 15 ml tube containing the swab/s should be carefully transported to the hospital laboratory as soon as possible in cold chain.
Sample processing:
The received swabs inside the 15 ml tube should be agitated vigorously for 10 seconds using a vortex mixer to free cells from the swab tip, and then both swabs should be removed from the tube and discarded using a forceps. The VTM should be split into 2 pre-labeled, sterile cryovials with the correct patient ID. One cryovial should be immediately placed in a freezer (-70°C), while the other cryovial will be used the molecular testing by real time PCR at MASRI-molecular laboratory.
Samples will be tested by real time multiplex PCR using FTD- respiratory 33 kit for the presence of a wide panel of respiratory pathogens that include: influenza A and subtypes influenza A Pdm(H1N1) and seasonal H3, influenza B, influenza C, parainfluenza viruses 1, 2, 3 and 4; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A and B; rhinovirus; respiratory syncytial viruses A and B ; adenovirus; enterovirus; parechovirus; Boca virus; Pneumocystis jirovecii; Mycoplasma pneumoniae; Chlamydia pneumoniae; Streptococcus pneumoniae; Haemophilus influenza type B (HIB assay also detects Haemophilus parahaemolyticus which is associated with pharyngitis); Staphylococcus aureus; Moraxella catarrhalis; Bordetella spp. (except Bordetella parapertussis), Klebsiella pneumoniae; Legionella species and Salmonella species. Cases suspected with MERS-CoV or HPAI H5N1 according to their history of contact with birds or camels or with reference to the WHO suspected cases of MERS-CoV or avian influenza will be tested using the CDC protocol.
Sample storage:
The second aliquot of the samples will be stored in freezers (-70°C) at MASRI MOLECULAR laboratory for External Quality Assurance (EQA) by on site testing through random selection of samples with different results and retest them by other NAMRU-3 laboratory expertise in MASRI molecular labs; the samples can also be used for further testing by NGS or virus isolation in MASRI molecular laboratories.
Sample Transfer:
All samples will be kept in Faculty of Medicine Ain Shams Research Institute- Molecular Unit laboratories and will not be transferred to other laboratories.
B- Explore study testing for COVID-19 using ready to use RT-real time test assays - VIRAL RNA ISOLATION: Using commercially available kits supplied by thermofisher or other recommended companies. Work will be done in Biosafety level 2 cabinets under complete sterile conditions. -
COVID-19 DETECTION:
Using real-time reverse transcription polymerase chain reaction RT-PCR the test can be done on respiratory samples obtained by various methods, including nasopharyngeal swab or sputum sample. Results are generally available within a few hours. Molecular methods leverage polymerase chain reaction (PCR) along with nucleic acid tests, and other advanced analytical techniques, to detect the genetic material of the virus using real-time reverse transcription polymerase chain reaction for diagnostic purposes. Commercially available kits supplied by hvd, thermofisher and others.
C- Genome sequencing (NGS) for possible positive covid-19 samples Ion Torrent targeted next-generation sequencing (NGS) enables a streamlined research workflow for complete genome sequencing and epidemiological studies of SARS-CoV-2 (the coronavirus responsible for COVID-19). Through the use of a set of highly specific, universal coronavirus primers in combination with a high-fidelity master mix, all genomic segments are amplified and the DNA amplicons are sequenced on any Ion Torrent system to deliver highly accurate coronavirus typing in under a day. The Ion ArnpliSeq SARS-CoV-2 Research Panel consists of 2 pools with arnplicons ranging from 125275 bp iri length for complete viral genome sequencing
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 1 year to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- hospitalized patients who meet the WHO standard SARI case definition
Key inclusion criteria (1 listed)
- 500 case presented from November 2019-February 2020 will be included in explore study from Ain shams university Hospitals
Key exclusion criteria (1 listed)
- Inadequate samples
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exploring the presence of COVID-19
Time frame: 9 months
Exploring the presence of COVID-19 in very well preserved oropharyngeal samples since November 2019
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2020.
- Individual participant dataSharing planned: No
Related trials for Coronavirus Disease (COVID-19)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara Hassan principal investigator
Ain Shams University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronavirus Disease (COVID-19) and COVID-19, run by Ain Shams University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sara Hassan (01223431070, sarakariem@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exploring the presence of COVID-19 (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2020.